leadXpro and Boehringer Ingelheim collaborate on membrane protein drug target

Biberach, Germany, & Villigen, Switzerland, 6 November 2016 Boehringer Ingelheim and leadXpro AG announce a collaboration to enter a partnership to enable structure based drug discovery and the use of biophysical methods for the advance projects for challenging membrane protein drug targets.

Integral membrane proteins are responsible for key signaling and metabolic mechanisms in humans and are excellent drug targets. leadXpro has deep expertise in protein generation, biophysical and structure-based methods including serial crystallography and cryo-electron microscopy (cryo-EM), and applies these advanced techniques to the discovery and optimisation of innovative lead compounds targeting membrane proteins, such as GPCRs, ion channels and transporters.

In the collaboration, Boehringer Ingelheim and leadXpro AG will combine their expertise in membrane protein generation, crystallization and X-ray structure analysis to enable structure based drug discovery of novel lead molecules. The collaboration will include the use of leadXpro expertise in serial crystallography done at synchrotron and free electron laser to improve diffraction and enable structure determination.


About Boehringer Ingelheim

Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects through, for example, the initiative “Making More Health” while also caring for employees. Respect, equal opportunity and reconciling career and family form the foundation of mutual cooperation. The company also focuses on environmental protection and sustainability in everything it does.

In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales.
For more information please visit www.boehringer-ingelheim.com